EA032478B1 - Способ производства обогащённой композиции иммуноглобулинов из плазмы или криообеднённой плазмы - Google Patents

Способ производства обогащённой композиции иммуноглобулинов из плазмы или криообеднённой плазмы Download PDF

Info

Publication number
EA032478B1
EA032478B1 EA201491564A EA201491564A EA032478B1 EA 032478 B1 EA032478 B1 EA 032478B1 EA 201491564 A EA201491564 A EA 201491564A EA 201491564 A EA201491564 A EA 201491564A EA 032478 B1 EA032478 B1 EA 032478B1
Authority
EA
Eurasian Patent Office
Prior art keywords
var
plasma
suspension
fraction
immunoglobulins
Prior art date
Application number
EA201491564A
Other languages
English (en)
Russian (ru)
Other versions
EA201491564A1 (ru
Inventor
Леопольд Брукшвайгер
Томас Гундингер
Юлиа Нюрнбергер
Вольфганг Тешнер
Ханс-Петер Шварц
Original Assignee
Баксалта Инкорпорейтид
Баксалта Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47833446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA032478(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Баксалта Инкорпорейтид, Баксалта Гмбх filed Critical Баксалта Инкорпорейтид
Publication of EA201491564A1 publication Critical patent/EA201491564A1/ru
Publication of EA032478B1 publication Critical patent/EA032478B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201491564A 2012-02-23 2013-02-25 Способ производства обогащённой композиции иммуноглобулинов из плазмы или криообеднённой плазмы EA032478B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261602488P 2012-02-23 2012-02-23
PCT/US2013/027681 WO2013126904A1 (en) 2012-02-23 2013-02-25 Fraction i-iv-1 precipitation of immunoglobins from plasma

Publications (2)

Publication Number Publication Date
EA201491564A1 EA201491564A1 (ru) 2015-04-30
EA032478B1 true EA032478B1 (ru) 2019-06-28

Family

ID=47833446

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491564A EA032478B1 (ru) 2012-02-23 2013-02-25 Способ производства обогащённой композиции иммуноглобулинов из плазмы или криообеднённой плазмы

Country Status (25)

Country Link
US (1) US9782477B2 (enExample)
EP (2) EP4119574A1 (enExample)
JP (1) JP6291423B2 (enExample)
KR (1) KR101930582B1 (enExample)
CN (1) CN104245730B (enExample)
AR (1) AR090425A1 (enExample)
AU (1) AU2013203112B2 (enExample)
BR (1) BR112014020602B1 (enExample)
CA (1) CA2864715A1 (enExample)
CL (1) CL2014002225A1 (enExample)
CO (1) CO7081143A2 (enExample)
DK (1) DK2817334T3 (enExample)
EA (1) EA032478B1 (enExample)
ES (1) ES2928954T3 (enExample)
HU (1) HUE060195T2 (enExample)
IL (1) IL234103B (enExample)
MX (2) MX365236B (enExample)
MY (1) MY167235A (enExample)
NZ (1) NZ628529A (enExample)
PL (1) PL2817334T3 (enExample)
PT (1) PT2817334T (enExample)
SG (1) SG11201405149UA (enExample)
SI (1) SI2817334T1 (enExample)
TW (1) TWI629283B (enExample)
WO (1) WO2013126904A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN104004090A (zh) * 2014-06-12 2014-08-27 新疆德源生物工程有限公司 一种人免疫球蛋白的制备方法
CN104004091B (zh) * 2014-06-12 2016-08-17 新疆德源生物工程有限公司 一种人免疫球蛋白的制备工艺
GB201413227D0 (en) 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
ES2887588T3 (es) * 2015-08-13 2021-12-23 Kamada Ltd Composiciones derivadas de pasta de fracción de Cohn y uso de las mismas
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
IL278584B2 (en) * 2018-05-17 2025-08-01 Csl Behring Ag Method and system of protein extraction
CA3157446A1 (en) 2019-11-20 2021-05-27 Csl Behring Ag Method for extracting a protein from a precipitate and method for precipitating impurities
EP4118108A4 (en) * 2020-04-10 2024-05-15 Plasma Technologies, LLC COMPOSITIONS AND METHODS FOR HIGHLY EFFICIENT SIMPLIFIED PROTEIN ISOLATION
EP4240757A2 (en) * 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
CN112250757A (zh) * 2020-11-13 2021-01-22 广东深蓝生物科技有限公司 一种猪血浆中蛋白质的提取纯化方法
JP2024501025A (ja) * 2020-12-28 2024-01-10 プラズマ テクノロジーズ エルエルシー 免疫グロブリンｇのプロセススケールでの単離のためのシステム及び方法
CN118580342B (zh) * 2024-05-20 2025-02-07 广东丹霞生物制药有限公司 一种静脉注射用人免疫球蛋白制剂的制备工艺

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476109A (en) * 1981-09-29 1984-10-09 Fujirebio Kabushiki Kaisha Method of preparing gamma globulin suitable for intravenous administration
WO2003034982A2 (en) * 2001-10-19 2003-05-01 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
WO2010138736A2 (en) * 2009-05-27 2010-12-02 Baxter International Inc. A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
WO2011149472A1 (en) * 2010-05-26 2011-12-01 Baxter International Inc. Method for preparing an enriched igg composition from plasma

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US3998946A (en) 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
US6284874B1 (en) 1994-06-17 2001-09-04 Alpha Therapeutic Corporation Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
CA2232420A1 (en) 1997-03-19 1998-09-19 The Green Cross Corporation Immunoglobulin preparation and preparation process thereof
GB9705810D0 (en) * 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
CA2251342A1 (en) 1997-10-23 1999-04-23 Yutaka Hirao Room temperature storable immunoglobulin preparation for intravenous injection
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
EP1413860A4 (en) * 2001-07-05 2009-02-25 Hamamatsu Photonics Kk SPECTROSCOPIC DEVICE
DK1664123T4 (da) 2003-09-22 2012-03-05 Kamada Ltd Storskalafremstilling af alfa-1-proteinaseinhibitor og anvendelse deraf
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
ES2595059T3 (es) 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
WO2011011753A1 (en) 2009-07-23 2011-01-27 Baxter International Inc. Manufacture of factor h (fh) and fh-derivatives from plasma
US8772462B2 (en) * 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
EP2596014B1 (en) 2010-07-23 2018-11-28 Baxalta GmbH Manufacture of inter-alpha-inhibitor proteins (iaip) from plasma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476109A (en) * 1981-09-29 1984-10-09 Fujirebio Kabushiki Kaisha Method of preparing gamma globulin suitable for intravenous administration
WO2003034982A2 (en) * 2001-10-19 2003-05-01 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
WO2010138736A2 (en) * 2009-05-27 2010-12-02 Baxter International Inc. A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
WO2011149472A1 (en) * 2010-05-26 2011-12-01 Baxter International Inc. Method for preparing an enriched igg composition from plasma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUCHACHER ANDREA; IBERER GUENTER: "Purification of intravenous immunoglobulin G from human plasma - aspects of yield and virus safety", BIOTECHNOLOGY JOURNAL, WILEY-VCH VERLAG, WEINHEIM, DE, vol. 1, no. 2, 1 February 2006 (2006-02-01), DE, pages 148 - 163, XP009141576, ISSN: 1860-6768 *
KISTLER P, NITSCHMANN H: "LARGE SCALE PRODUCTION OF HUMAN PLASMA FRACTIONS", VOX SANGUINIS., S. KARGER AG, BASEL., CH, vol. 07, 1 January 1962 (1962-01-01), CH, pages 414 - 424, XP001048178, ISSN: 0042-9007 *
RADOSEVICH M; BURNOUF T: "Intravenous immunoglobulin G: Trends in production methods, quality control and quality assurance", VOX SANGUINIS., S. KARGER AG, BASEL., CH, vol. 98, no. 1, 1 January 2010 (2010-01-01), CH, pages 12 - 28, XP009141581, ISSN: 0042-9007, DOI: 10.1111/j.1423-0410.2009.01226.x *

Also Published As

Publication number Publication date
IL234103B (en) 2019-11-28
CA2864715A1 (en) 2013-08-29
HUE060195T2 (hu) 2023-02-28
BR112014020602B1 (pt) 2022-12-20
PL2817334T3 (pl) 2022-11-21
SG11201405149UA (en) 2014-09-26
IL234103A0 (en) 2014-09-30
EP2817334A1 (en) 2014-12-31
ES2928954T3 (es) 2022-11-23
TW201348248A (zh) 2013-12-01
CN104245730B (zh) 2017-09-01
BR112014020602A2 (pt) 2018-09-11
MY167235A (en) 2018-08-14
EP4119574A1 (en) 2023-01-18
TWI629283B (zh) 2018-07-11
AR090425A1 (es) 2014-11-12
CO7081143A2 (es) 2014-10-10
KR101930582B1 (ko) 2018-12-18
MX365236B (es) 2019-05-28
JP2015509506A (ja) 2015-03-30
PT2817334T (pt) 2022-10-17
CL2014002225A1 (es) 2015-01-16
EP2817334B1 (en) 2022-09-21
MX2019005999A (es) 2019-08-21
WO2013126904A1 (en) 2013-08-29
US20130224183A1 (en) 2013-08-29
MX2014010076A (es) 2014-09-22
HK1205520A1 (en) 2015-12-18
SI2817334T1 (sl) 2022-11-30
NZ628529A (en) 2016-09-30
AU2013203112B2 (en) 2016-03-10
AU2013203112A1 (en) 2013-09-12
EA201491564A1 (ru) 2015-04-30
JP6291423B2 (ja) 2018-03-14
CN104245730A (zh) 2014-12-24
US9782477B2 (en) 2017-10-10
KR20140135996A (ko) 2014-11-27
DK2817334T3 (da) 2022-10-03

Similar Documents

Publication Publication Date Title
KR101930582B1 (ko) 혈장으로부터 면역글로빈의 분획 i-iv-1 침전
EA025826B1 (ru) Удаление сериновых протеаз путем обработки тонкоизмельченным диоксидом кремния
EP2748193B1 (en) Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
JP2011102314A (ja) 静脈投与用免疫グロブリン及び他の免疫グロブリン生成物の製造法
JP7717715B2 (ja) Ｃ－１インヒビター欠乏血漿から免疫グロブリン製剤を生産する方法
HK40086420A (en) Fraction i-iv-1 precipitation of immunoglobins from plasma
EA045585B1 (ru) Способ получения препарата иммуноглобулина из плазмы с низким содержанием ингибитора c-1
HK1205520B (en) Fraction i-iv-1 precipitation of immunoglobins from plasma
HK1199267B (en) Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

PC4A Registration of transfer of a eurasian patent by assignment